Answers are grounded in this paper and cite their sources.
Review shows extracellular vesicles could serve as blood biomarkers for synucleinopathies, suggesting that unproven brain origin and analytical variability currently hinder clinical translation.
Synucleinopathies are defined by pathological α-synuclein states, including conformation, aggregation, modification, and seeding competence, that abundance alone cannot capture. Extracellular vesicles may preserve these states during transit from brain to blood, but mechanistic plausibility, diagnostic discrimination, and brain provenance are distinct claims. We argue that proteomics can interrogate vesicle identity, cargo and proteoforms, while unresolved provenance, pre-analytical variability, and incomplete clinical validation leave the biochemical biopsy concept plausible but unvalidated.
No takes yet. Share an insight, caveat, or question.
Weber et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: